

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

**IN RE: GENERIC PHARMACEUTICALS
PRICING ANTITRUST LITIGATION**

MDL NO. 2724

16-MD-2724

THIS DOCUMENT RELATES TO:

HON. CYNTHIA M. RUFE

Direct Purchaser Class Plaintiffs' Actions

MEMORANDUM OPINION

Rufe, J.

July 16, 2026

Direct Purchaser Plaintiffs César Castillo, LLC, FWK Holdings, LLC, Rochester Drug Cooperative, Inc., and KPH Healthcare Services, Inc. a/k/a/ Kinney Drugs, Inc. (“DPPs”) seek final approval of a settlement with Glenmark Pharmaceutical Inc. (“Glenmark”) and with Greenstone LLC and Pfizer Inc. (“Greenstone/Pfizer”) (collectively “Settling Defendants”).

Under Federal Rule of Civil Procedure 23(e), the Court held a hearing on April 8, 2026, to determine whether the proposed class action settlements are “fair, reasonable, and adequate.”¹ The Court must: (1) determine if the requirements for class certification under Rule 23(a) and (b) are satisfied; (2) assess whether notice to the proposed class was adequate; and (3) evaluate if the proposed settlement is fair under Rule 23(e).² Preliminarily, the Court finds that Glenmark caused timely notice of the settlement and related materials to be sent to the Attorney General of the United States and the Attorneys General of all U.S. states, territories, and the District of

¹ Fed. R. Civ. P. 23(e)(2).

² See *In re Nat'l Football League Players Concussion Inj. Litig.*, 775 F.3d 570, 581 (3d Cir. 2014).

Columbia pursuant to the Class Action Fairness Act of 2005 (“CAFA”).³ At the Final Approval Hearing, the Court identified that Greenstone/Pfizer had not caused timely CAFA notice to be sent to the required individuals.⁴ Greenstone/Pfizer has since provided adequate notice, and the 90-day period for response has lapsed without objection.⁵ The Court finds that such notification complies with the applicable requirements of CAFA.

There are no objections to either settlement.⁶

I. RULE 23(A)

To certify a class, the Court must determine that the following factors are met: numerosity, commonality, typicality, and adequacy of representation.⁷

The Court preliminarily approved the following DPP Glenmark Settlement Class:

All persons or entities, and their successors and assigns, that directly purchased one or more of the Named Generic Drugs from one or more Current or Former Defendants in the United States and its territories and possessions, at any time during the period from May 1, 2009 until December 31, 2019.

Excluded from the Settlement Class are Current and Former Defendants and their present and former officers, directors, management, employees, subsidiaries, or affiliates, judicial officers and their personnel, and all governmental entities.⁸

The Court preliminarily approved the following DPP Greenstone/Pfizer Settlement Class:

All persons or entities, and their successors and assigns, that directly purchased one or more of the Named Generic Drugs from one or more Current or Former Defendants in the United States and its territories and

³ 4/8/26 Final Approval Hr’g Tr.

⁴ *Id.*

⁵ Greenstone/Pfizer 7/14/26 Letter, Bingham Dec. [MDL Doc. No. 4747].

⁶ Mem. Law Supp. Mot. Final Approval of Glenmark Settlement at 1 [MDL Doc. No.4097]; Mem. Law Supp. Mot. Final Approval of Greenstone/Pfizer Settlement at 1 [MDL Doc. No. 4096]; *see also* Decl. of Eric Miller [MDL Doc. No. 4001-1].

⁷ Fed. R. Civ. P. 23(a).

⁸ Order Prelim. Approve Glenmark Settlement at 2 [MDL Doc. No. 3623].

possessions, at any time during the period from May 1, 2009 until December 31, 2019.

Excluded from the Settlement Class are Current and Former Defendants and their present and former officers, directors, management, employees, subsidiaries, or affiliates, judicial officers and their personnel, and all governmental entities.⁹

Both classes contain an identical set of class members.

Upon careful consideration, the Court will certify the Settlement Classes. The Rule 23(a) factors are satisfied. Numerosity is satisfied as the Settlement Classes each include more than 700 members geographically dispersed throughout the United States.¹⁰ A single common issue is enough to satisfy the commonality requirement, and typicality is met where “the action can be efficiently maintained as a class and . . . the named plaintiffs have incentives that align with those of absent class members so as to assure that the absentee’s interests will be fairly represented.”¹¹ Here, there are common issues of law and fact as to all class members: that they made direct purchases of generic pharmaceuticals within the defined class period that were priced higher than they should have been because of an alleged conspiracy among manufacturers, including the Settling Defendants.

Plaintiffs have also demonstrated that the “representative parties will fairly and adequately protect the interests of the class.”¹² The named Plaintiffs’ interests align with those of other class members. The Settlement Agreements provide that each of the four class representatives will receive a service award of \$20,000, for a total of \$80,000. The service awards will be equally provided from the Glenmark Settlement and the Greenstone/Pfizer

⁹ Order Prelim. Approve Greenstone/Pfizer Settlement at 2 [MDL Doc. No. 3620].

¹⁰ Mem. Law Supp. Mot. Prelim. Approve Glenmark Settlement at 13 [MDL Doc. No. 3593-1]; Mem. Law Supp. Prelim. Approve Greenstone/Pfizer Settlement at 13 [MDL Doc. No. 3596-1]; *see also* Decl. of Eric Miller [MDL Doc. No. 4001-1].

¹¹ *Baby Neal v. Casey*, 43 F.3d 48, 56–57 (3d Cir. 1994).

¹² Fed. R. Civ. P. 23(a)(4).

Settlement such that a total of \$40,000 will be provided from each Settlement. In the context of the Settlement Awards as discussed below, the Court finds this a reasonable amount, as the representatives have been actively involved in the prosecution of the case, including through depositions and extensive document production. Class counsel are qualified, experienced, and fully capable of litigating the class members' claims.¹³ The representative Plaintiffs and class counsel have protected the interests of the classes in crafting adjusted settlement amounts that will be allocated on a *pro rata* basis. No objections have been filed against the proposed Plan of Allocation.¹⁴ Each Settlement reserves, for the purposes of joint and several liability against non-settling Defendants, DPPs' ability to rely on Glenmark's and Greenstone/Pfizer's sales of Named Generic Drugs ("NGD") to the Settlement Class to seek the full amount of damages to which they may be entitled from any other Defendant in the MDL.

In addition, the Settling Defendants have agreed to provide cooperation to DPPs, which will facilitate the administration of the settlements and will aid the litigation against non-settling Defendants.

II. RULE 23(B)

The Settlement Classes each also satisfy at least one of the three requirements listed in Rule 23(b).¹⁵ The Court finds that "questions of law or fact common to class members predominate over any questions affecting only individual members, and that a class action is superior to other available methods for fairly and efficiently adjudicating the controversy."¹⁶ The alleged collusive conduct by Settling Defendants affected all class members in the same way

¹³ *In re Warfarin Sodium Antitrust Litig.*, 391 F.3d 516, 532 (3d Cir. 2004).

¹⁴ Mem. Law Supp. Mot. Final Approval of Glenmark Settlement at 10 [MDL Doc. No.4097]; Mem. Law Supp. Mot. Final Approval of Greenstone/Pfizer Settlement at 10 [MDL Doc. No. 4096].

¹⁵ *Wal-Mart Stores, Inc. v. Dukes*, 564 U.S. 338, 345 (2011) (citations omitted).

¹⁶ Fed. R. Civ. P. 23(b)(3).

with regard to the cost of generic pharmaceuticals.¹⁷ DPPs have shown that, for the purposes of the Settlements, a class action is a fair and efficient way to resolve the dispute in light of “alternative available methods of adjudication.”¹⁸ As directed by Rule 23(b)(3), the Court has considered: “(A) the interest of members of the class in individually controlling the prosecution or defense of separate actions; (B) the extent and nature of any litigation concerning the controversy already commenced by or against members of the class; [and] (C) the desirability or undesirability of concentrating the litigation of the claims in the particular forum. . . .”¹⁹

Although some Plaintiffs are proceeding individually in the MDL, given the complexity of the litigation, over 700 individual actions are not likely to be a more desirable way of proceeding, and “[a] class action is therefore superior to other methods of adjudication” in the context of the Settlements.²⁰

In the Third Circuit, Rule 23(b)(3) also requires that class be “currently and readily ascertainable based on objective criteria.”²¹ This ascertainability requirement is two-fold: “(1) the class is defined with reference to objective criteria; and (2) there is a reliable and administratively feasible mechanism for determining whether putative class members fall within the class definition.”²² Here, the class is ascertainable because the class is defined with reference to the objective criteria of whether class members, which are sophisticated parties, directly

¹⁷ *In re Processed Egg Prods. Antitrust Litig.*, 284 F.R.D. 249, 263 (E.D. Pa. 2012) (citing *Sullivan v. DB Invs., Inc.*, 667 F.3d 273, 297 (3d Cir. 2011)).

¹⁸ *In re Warfarin Sodium Antitrust Litig.*, 391 F.3d 516, 534 (3d Cir. 2004) (citations omitted).

¹⁹ Fed. R. Civ. P. 23(b)(3).

²⁰ *McDermid v. Inovio Pharms., Inc.*, No. 20-1402, 2023 WL 227355, at *3 (E.D. Pa. Jan. 18, 2023) (citations omitted).

²¹ *In re Niaspan Antitrust Litig.*, 67 F.4th 119, 129-30 (3d Cir. 2023) (quoting *Hargrove v. Sleepy’s LLC*, 974 F.3d 467, 477 (3d Cir. 2020)).

²² *Hargrove*, 974 F.3d. at 469–70 (quoting *Byrd v. Aaron’s Inc.*, 784 F.3d 154, 163 (3d Cir. 2015)).

purchased the named generic drugs from Settling Defendants. The class can be reliably determined using Defendants' transactional data, and there is a mechanism for class members who are not identified in the transactional data to provide supporting evidence of their direct purchases. The class satisfies the requirements of ascertainability. The Court therefore certifies the Settlement Classes for purposes of the final Settlement Agreements.

III. NOTICE

As part of the preliminary approvals, the Court directed that notice of both Settlement Agreements be provided.²³ The notice for the Settlements clearly and concisely stated in plain, easily understood language: “(i) the nature of the action[s]; (ii) the definition of the class[es] preliminarily certified; (iii) the class[es'] claims, issues, or defenses; (iv) that a class member may enter an appearance through an attorney if the member so desires; (v) that the court will exclude from the class[es] any member who requests exclusion; (vi) the time and manner for requesting exclusion; and (vii) the binding effect of a class judgment on members under Rule 23(c)(3).”²⁴

Notice was made through direct mail to direct purchasers, using Defendants' transactional data, through the use of digital banner ads on a website targeted to reach likely direct purchasers, through publication in *The Wall Street Journal*, and through a news release via Business Wire, as well as with the use of a case-specific toll-free telephone number, email address, and website.²⁵ This notice complies with the Court's Orders regarding notice and satisfies the requirements of Rule 23.

²³ Order Prelim. Approve Glenmark Settlement ¶¶ 15-21 [MDL Doc. No. 3623]; Order Prelim. Approve Greenstone/Pfizer Settlement ¶¶ 15-21 [MDL Doc. No. 3620].

²⁴ Fed. R. Civ. P. 23(c)(2)(B).

²⁵ Decl. Eric J. Miller [MDL Doc. No. 4001-1].

IV. RULE 23(E) AND THE *GIRSH* FACTORS

The Court determines that the proposed Settlements are “fair, reasonable, and adequate.”²⁶ A settlement is fair where “(1) the settlement negotiations occurred at arm’s length; (2) there was sufficient discovery; (3) the proponents of the settlement are experienced in similar litigation; and (4) only a small fraction of the class objected.”²⁷ Each of these factors is met for each Settlement. There have been no objections to the Settlements.²⁸ Negotiations occurred at arm’s length with experienced and accomplished counsel over a significant period of time and there has been extensive discovery in the MDL, enabling class counsel to “develop enough information about the [litigation] to appreciate sufficiently the value of the claims.”²⁹

As required by Rule 23(e)(2), the Court determines that the relief provided to the classes is adequate.³⁰ The Glenmark Settlement amount consists of a \$37,750,000 payment, which has

²⁶ *In re Prudential Ins. Co. Am. Sales Prac. Litig. Agent Actions*, 148 F.3d 282, 316 (3d Cir. 1998) (quoting *In re Gen. Motors Corp. Pick-Up Truck Fuel Tank Prods. Liab. Litig.*, 55 F.3d 768, 785 (3d Cir. 1995)); see also Fed. R. Civ. P. 23(e).

²⁷ *In re Warfarin*, 391 F.3d at 535 (quoting *In re Cendant Corp. Litig.*, 264 F.3d 201, 232 n. 18 (3d Cir. 1998)).

²⁸ Decl. Eric J. Miller ¶ 22 [MDL Doc. No. 4001-1].

DPPs received eight timely requests to opt out from the Glenmark Settlement on behalf of 381 entities. Only 42 of these entities, all of which are Direct Action Plaintiffs in the MDL, have been identified as potential Glenmark Settlement Class Members based on transactional data from the Settling Defendants. Decl. Eric J. Miller ¶¶ 16-19 [MDL Doc. No. 4001-1].

DPPs received six timely requests to opt out from the Greenstone/Pfizer Settlement on behalf of 330 entities. Only 32 of these entities, all of which are Direct Action Plaintiffs in the MDL, have been identified as potential Greenstone/Pfizer Settlement Class Members based on transactional data from the Settling Defendants. Decl. Eric J. Miller ¶¶ 16-19 [MDL Doc. No. 4001-1].

²⁹ *In re Nat’l Football League Players Concussion Injury Litig.*, 821 F.3d 410, 439 (3d Cir. 2016).

³⁰ Rule 23(e)(2) requires the Court to determine that:

(A) the class representatives and class counsel have adequately represented the class; (B) the proposal was negotiated at arm’s length; (C) the relief provided for the class is adequate, taking into account: (i) the costs, risks, and delay of trial and appeal; (ii) the effectiveness of any proposed method of distributing relief to the class, including the method of processing class-member claims; (iii) the terms of any proposed award of attorney’s fees, including timing of payment; and (iv) any agreement required to be identified under Rule 23(e)(3); and (D) the proposal treats class members equitably relative to each other.

Fed. R. Civ. P. 23(e)(2).

been reduced to \$33,220,000 to account for opt-outs, but may be increased to \$47,170,512.50 under the most favored nation clause.³¹ The Greenstone/Pfizer Settlement amount consists of a \$33,000,000 payment, which has been or will be reduced to \$29,040,000 to account for opt-outs, but may be increased to \$41,235,150 under the most favored nation clause.³²

In addition to the service awards discussed above, class counsel seek disbursement of \$6,000,000 in unreimbursed expenses.³³ \$3,000,000 of the unreimbursed expenses would be provided from the Glenmark Settlement and \$3,000,000 of the unreimbursed expenses would be provided from the Greenstone/Pfizer Settlement.³⁴ Class counsel have demonstrated that the expenses sought are reasonable and they will be approved.

Finally, class counsel seek attorneys' fees of one-third of each net Settlement Fund, inclusive of interest.³⁵ The Court incorporates by reference the separate Order approving attorneys' fees for both Settlements that will be entered with this Memorandum Opinion.³⁶

The relief the Settlements are expected to provide class members is adequate when balanced against "(i) the costs, risks, and delay of trial and appeal; (ii) the effectiveness of any proposed method of distributing relief to the class, including the method of processing class-member claims; (iii) the terms of any proposed award of attorney's fees, including timing of payment; and (iv) any agreement required to be identified under Rule 23(e)(3)."³⁷ In addition to the inherent risk to recovery involved in prolonged litigation, continuing through motions

³¹ Mem. Law. Supp. Mot. Final Approval Glenmark Settlement at 5-6 [MDL Doc. No. 4097].

³² Mem. Law. Supp. Mot. Final Approval Greenstone/Pfizer Settlement at 5 [MDL Doc. No. 4096].

³³ Mem. Law Supp. Mot. for Atty. Fees at 2 [Doc. No. 3828-1].

³⁴ *Id.* at 5-6.

³⁵ *Id.* at 8-9.

³⁶ DPPs seek attorney's fees from set-aside funds in connection with previous settlements; for the sake of transparency, the Court addresses the fee requests separately.

³⁷ Fed. R. Civ. P. 23(e)(2)(C)(i)–(iv).

regarding class certification, the dismissal of claims, and the exclusion of evidence, as well as potential trials and appeals would only delay any recovery class members may receive.

Rule 23(e)(2)(iv) requires the Court to account for any agreements between the parties required to be identified under Rule 23(e)(3), referring to “any agreement made in connection with the [Settlement] proposal[s].”³⁸ The Settlement documents set forth the relevant agreements, including that the settling parties have agreed that that Settling Defendants’ sales remain in the MDL for purposes of joint and several liability as to non-settling Defendants to the extent permitted or authorized by law, and that the Settling Defendants will provide cooperation, both in terms of effectuating the settlement and providing information to help in the continued litigation against the non-settling Defendants.

The final element of Rule 23(e)(2) requires the Court to determine whether the proposals treat the class members equitably relative to each other. As discussed above, the Settlements’ funds will be allocated on a *pro rata* basis, which treats the class members equitably.

In addition to satisfying the standard under Rule 23, the factors set forth by the Third Circuit in *Girsh v. Jepson*, 521 F.2d 153, 157 (3d Cir. 1975), also favor settlement. The *Girsh* factors are “(1) the complexity, expense and likely duration of the litigation; (2) the reaction of the class to the settlement; (3) the stage of the proceedings and the amount of discovery completed; (4) the risks of establishing liability; (5) the risks of establishing damages; (6) the risks of maintaining the class action through the trial; (7) the ability of the defendants to withstand a greater judgment; (8) the range of reasonableness of the settlement fund in light of the best possible recovery; [and] (9) the range of reasonableness of the settlement fund to a

³⁸ Fed. R. Civ. P. 23(e)(3).

possible recovery in light of all the attendant risks of litigation.” *Id.* These factors generally have been discussed in connection with Rule 23(e).

The litigation is extremely complex and, in the absence of the settlement, it would likely be several years before all of the claims asserted by DPPs are resolved. No class members have objected to the settlement, and potential class members have been able to opt out of the settlement. There has been extensive motion practice and discovery through which the parties have learned of the claims. Settling Defendants have denied liability, and in the absence of the settlement, DPPs would be required to litigate issues of liability, damages, and class certification. There remain many other claims asserted against Settling Defendants and settlement at this time assures a fair payment to the DPPs on their claims against these Defendants. Considering all of the attendant risks of litigation of DPPs’ claims, including within the broader context of the MDL, the Court concludes that the settlement is reasonable under the *Girsh* factors.

V. CONCLUSION

The Court having determined that the Settlements are fair and reasonable, and that all applicable requirements have been met, the Court will approve the Settlements. Appropriate orders will be entered.